The addition of ibrutinib to standard R-CHOP chemotherapy improved EFS, PFS and OS among patients aged younger than 60 years with untreated nongerminal center B-cell diffuse large B-cell lymphoma, ...

Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes Subjects were 469 patients with histologically confirmed ...

DLBCL is the most common non-Hodgkin lymphoma, affecting over 18,000 people annually in the U.S., primarily those over 60. Standard R-CHOP chemotherapy is effective for many DLBCL patients, but ...

The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as first-line treatment in patients with diffuse large B-cell lymphomas is still a matter of debate. To address ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The addition of ...

The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly diagnosed diffuse large B-cell lymphoma, according to study results published in Journal of ...

High-risk patients with diffuse large B-cell lymphoma (DLBCL) may benefit from being treated with a regimen that adds zanubrutinib and lenalidomide to R-CHOP (a combination of the monoclonal antibody ...

Patients with no prior chemotherapy and with advanced and progressive follicular lymphoma (FCL) or mantle cell lymphoma (MCL) were enrolled into a treatment protocol combining CHOP/rituximab–CHOP ...

June 7, 2011, 4:46 PM EDT / Source: GlobeNewswire Preliminary Results from Phase II Study of Yttrium-90-labeled Epratuzumab as Consolidation Treatment for Diffuse Large B-cell Lymphoma Reported at ...

Diffuse large B-cell lymphoma (DLBCL) grows fast, so you usually start treatment right away. The type you get depends on your overall health and stage of your cancer. For DLBCL, most people have ...

Patients with mantle cell lymphoma who were eligible for stem cell transplant saw a 97% overall response rate to a three-drug regimen, according to findings from two clinical trials. Patients with ...